title: Pharmacokinetics and pharmacodynamics of propafenone during acute and chronic administration.
abstract: The pharmacokinetics of propafenone and 5-OH-propafenone and their relationship with the antiarrhythmic action and side effects have been studied in 10 patients with stable, frequent, premature ventricular beats (224-928 premature ventricular complexes/h). Observations were made after a single dose of propafenone 300 mg p.o., and after 1 and 3 months (only 5 out of 10 patients) of therapy with 300 mg t.d.s. After 1 month of treatment the plasma elimination half-life of propafenone (6.7 h) was almost twice as long as after a single dose (3.5 h), and the area under the plasma propafenone concentration-time curve (7620 ng.ml-1.h) was significantly larger than after single dose (3522 ng.ml-1.h); this was also true for the metabolite. The ratio of the AUCs of 5-OH-propafenone and propafenone decreased from the single dose (0.63) to 1 month (0.32). These variables remained stable up to 3 months. Eight patients had greater than or equal to 75% reduction of premature ventricular complexes after 3 days of therapy, and in 7 they were completely suppressed; the response was maintained over 1 to 3 months. Side effects were minor and in no case had the drug to be withdrawn or the dose reduced. Thus, the kinetics of propafenone were time-dependent. Its active metabolite did not accumulate greatly during chronic treatment. The lasting antiarrhythmic effect observed in some patients suggests a b.d.s. regimen instead of t.d.s. dosing in selected patients.
authors: Divisione di Cardiologia, Seriate (Bergamo), Italy.
authors: P
authors: P
authors: Giani
authors: M
authors: M
authors: Landolina
authors: V
authors: V
authors: Giudici
authors: C
authors: C
authors: Bianchini
authors: G
authors: G
authors: Ferrario
authors: S
authors: S
authors: Marchi
authors: E
authors: E
authors: Riva
authors: R
authors: R
authors: Latini
mesh_terms: D000328:Adult; D000889:Anti-Arrhythmia Agents; D000959:Antihypertensive Agents; D004562:Electrocardiography; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D008875:Middle Aged; D011405:Propafenone / Q000009:adverse effects / Q000031:analogs & derivatives / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology
chemical_list: D000889:Anti-Arrhythmia Agents; D000959:Antihypertensive Agents; D011405:Propafenone; C044307:5-hydroxypropafenone